Breaking News Instant updates and real-time market news.

LGND

Ligand

$142.01

(0.00%)

09:44
01/10/19
01/10
09:44
01/10/19
09:44

Ligand mentioned cautiously at Grants Interest Rate Observer

LGND Ligand
$142.01

(0.00%)

10/29/18
10/29/18
UPGRADE
Target $195

Buy
Ligand upgraded to Buy on 'strong' fundamentals at Roth Capital
As previously reported, Roth Capital analyst Scott Henry upgraded Ligand to Buy from Neutral following a 40% decline in the share price. The analyst argues that fundamentals remain strong and lowered 2019 outlook should be more conservative. Further, Henry targets upside to shares even with more conservative numbers. The analyst lowered his price target on the shares to $195 from $250.
11/08/18
HCWC
11/08/18
NO CHANGE
Target $281
HCWC
Buy
Ligand selloff a 'compelling accumulation opportunity,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says the recent weakness in shares of presents a "compelling accumulation opportunity." The investment case on Ligand is "unchanged" following its Q3 results, Pantginis tells investors in a research note. He views the selloff as "healthy," noting the stock is "letting off of some steam after significant out-performance." The analyst reiterates a Buy rating on Ligand with a $281 price target.
11/13/18
SPHN
11/13/18
NO CHANGE
Target $200
SPHN
Overweight
Ligand recent pullback creates buying opportunity, says Stephens
Stephens analyst Drew Jones lowered his price target on Ligand shares to $200 from $248 following the recent pullback in the shares, but sees a buying opportunity given his expectations for solid royalty trends to remain intact. He thinks macro uncertainty continues to trump fundamentals, but believes company specific worries, such as Promacta competition, Kyprolis "lumpiness" and tough milestone comps for FY19, are "more distraction than material," he tells investors. Jones keeps an Overweight rating on Ligand shares.
11/19/18
HCWC
11/19/18
NO CHANGE
Target $281
HCWC
Buy
Ligand recent selloff 'disconnected from reality,' says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says the recent selloff in shares of Ligand Pharmaceuticals is "disconnected from reality." In a research note titled "Stop the Insanity; Physician Survey Refutes Potential Bear Scenario; Reiterate Buy," the analyst tells investors that the recent weakness represents a "unique opportunity, even in these volatile markets." In the end, the focus is on Ligand's growing royalty revenue line and the current pipeline of over 178 partnered assets, Pantginis tells investors in a research note. He reiterates a Buy rating on the shares with a $281 price target.

TODAY'S FREE FLY STORIES

STT

State Street

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Downgrade
State Street rating change  »

State Street downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

, KNX

Knight-Swift

$32.69

1.005 (3.17%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Recommendations
Werner, Knight-Swift analyst commentary  »

Deutsche Bank names…

WERN

Werner

KNX

Knight-Swift

$32.69

1.005 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Apr

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

, FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Upgrade
Palo Alto Networks, Fortinet rating change  »

Palo Alto Networks…

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

AIG

AIG

$44.15

0.86 (1.99%)

07:27
01/22/19
01/22
07:27
01/22/19
07:27
Recommendations
AIG analyst commentary  »

Deutsche Bank closes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Immunomedics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$4.92

0.015 (0.31%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Recommendations
GoPro analyst commentary  »

GoPro still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 25

    Feb

07:25
01/22/19
01/22
07:25
01/22/19
07:25
General news
FX Update »

FX Update: A generally…

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

ATI

Allegheny Technologies

$25.48

0.5 (2.00%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Earnings
Allegheny Technologies reports Q4 EPS 30c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IRMD

iRadimed

$25.77

0.32 (1.26%)

07:21
01/22/19
01/22
07:21
01/22/19
07:21
Hot Stocks
iRadimed suspends sales of 3880 patient vital signs monitoring system »

iRadimed announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Upgrade
Apollo Investment rating change  »

Citi upgrades Apollo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

FITB

Fifth Third

$27.00

0.59 (2.23%)

, MBFI

MB Financial

$44.59

0.83 (1.90%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Hot Stocks
Fifth Third sees FY19 NII up approx. 3% from FY18 »

Sees Q1 NII down 1.5%-2%…

FITB

Fifth Third

$27.00

0.59 (2.23%)

MBFI

MB Financial

$44.59

0.83 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

ICE

IntercontinentalExchange

, CME

CME Group

$183.47

2.25 (1.24%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Recommendations
IntercontinentalExchange, CME Group analyst commentary  »

Citi upgrades ICE to Buy,…

ICE

IntercontinentalExchange

CME

CME Group

$183.47

2.25 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 08

    May

  • 28

    May

MO

Altria Group

$48.29

1.22 (2.59%)

, PM

Philip Morris

$73.77

1.25 (1.72%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Downgrade
Altria Group, Philip Morris rating change  »

Altria Group downgraded…

MO

Altria Group

$48.29

1.22 (2.59%)

PM

Philip Morris

$73.77

1.25 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 18

    Feb

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

, AGN

Allergan

$160.28

3.74 (2.39%)

07:16
01/22/19
01/22
07:16
01/22/19
07:16
Periodicals
Aurinia CEO says VOS could become blockbuster treatment, STATNews reports »

Though Aurinia…

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

AGN

Allergan

$160.28

3.74 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 18

    May

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.